A MULTICENTRIC OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO PERIOD, TWO-SEQUENCE, CROSSOVER, STEADY STATE, DOSAGE STRENGTH EQUIVALENCE STUDY OF CLOZAPINE EXTENDED RELEASE CAPSULE 25 MG (LOWEST STRENGTH, 25 MG X 8 CAPSULES) ONCE DAILY (TEST DRUG, INTAS PHARMACEUTICALS LIMITED, INDIA) WITH CLOZAPINE EXTENDED RELEASE CAPSULE 200 MG (HIGHEST STRENGTH) ONCE DAILY (TEST DRUG, INTAS PHARMACEUTICALS LIMITED, INDIA) AFTER MULTIPLE DOSE ADMINISTRATION IN ADULT SCHIZOPHRENIC PATIENTS UNDER FASTING CONDITIONS.

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com